Hubbry Logo
AcetylcysteineAcetylcysteineMain
Open search
Acetylcysteine
Community hub
Acetylcysteine
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Acetylcysteine
Acetylcysteine
Acetylcysteine
View on Wikipedia
from Wikipedia

Acetylcysteine
Clinical data
Pronunciation/əˌsiːtəlˈsɪstiːn/ and similar (/əˌsɛtəl-, ˌæsɪtəl-, -tiːn/)
Trade namesACC 200, Acetadote, Fluimucil, Mucomyst, others
Other namesN-acetylcysteine; N-acetyl-L-cysteine; NALC; NAC
AHFS/Drugs.comMonograph
MedlinePlusa615021
License data
Pregnancy
category
  • AU: B2
Routes of
administration		Oral, intravenous, inhalation
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability6–10% (Oral)[7][8]
nearly 100% (intravenous)[9]
Protein binding50 to 83%[10]
MetabolismLiver[10]
Elimination half-life5.6 hours[6]
ExcretionKidney (30%),[10] faecal (3%)
Identifiers
  • (2R)-2-acetamido-3-sulfanylpropanoic acid[11]
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.009.545 Edit this at Wikidata
Chemical and physical data
FormulaC5H9NO3S
Molar mass163.19 g·mol−1
3D model (JSmol)
Specific rotation+5° (c = 3% in water)[12]
Melting point109 to 110 °C (228 to 230 °F) [12]
  • C/C(=N/[C@@H](CS)C(=O)O)/O
  • InChI=1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1
  • Key:PWKSKIMOESPYIA-BYPYZUCNSA-N

N-acetylcysteine or Acetylcysteine (NAC) (not to be confused with N-Acetylcarnosine, which is also abbreviated "NAC") is a mucolytic that is used to treat paracetamol (acetaminophen) overdose and to loosen thick mucus in individuals with chronic bronchopulmonary disorders, such as pneumonia and bronchitis.[10][13] It has been used to treat lactobezoar in infants. It can be taken intravenously, orally (swallowed by mouth), or inhaled as a mist by use of a nebulizer.[10][14] It is also sometimes used as a dietary supplement.[15][16]

Common side effects include nausea and vomiting when taken orally.[10] The skin may occasionally become red and itchy with any route of administration.[10] A non-immune type of anaphylaxis may also occur.[10] It appears to be safe in pregnancy.[10] For paracetamol overdose, it works by increasing the level of glutathione, an antioxidant that can neutralize the toxic breakdown products of paracetamol.[10] When inhaled, it acts as a mucolytic by decreasing the thickness of mucus.[17]

Acetylcysteine was initially patented in 1960 and came into medical use in 1968.[18][19][20] It is on the World Health Organization's List of Essential Medicines.[21] It is available as a generic medication.[22]

The sulfur-containing amino acids cysteine and methionine are more easily oxidized than the other amino acids.[23][24]

Uses

[edit]

Medical uses

[edit]

Paracetamol overdose antidote

[edit]
Main article: Paracetamol poisoning

Intravenous and oral formulations of acetylcysteine are available for the treatment of paracetamol (acetaminophen) overdose.[25] When paracetamol is taken in large quantities, a toxic minor metabolite called N-acetyl-p-benzoquinone imine (NAPQI) accumulates within the body. It is normally conjugated by glutathione, but when taken in excess, the body's glutathione reserves are not sufficient to deactivate the toxic NAPQI. This metabolite is then free to react with key hepatic enzymes, thereby damaging liver cells. This may lead to severe liver damage and even death by acute liver failure.

In the treatment of paracetamol (acetaminophen) overdose, acetylcysteine acts to maintain or replenish depleted glutathione reserves in the liver and enhance non-toxic metabolism of acetaminophen.[6] These actions serve to protect liver cells from NAPQI toxicity. It is most effective in preventing or lessening hepatic injury when administered within 8–10 hours after overdose.[6] Research suggests that the rate of liver toxicity is approximately 3% when acetylcysteine is administered within 10 hours of overdose.[25]

Although IV and oral acetylcysteine are equally effective for this indication, oral administration is generally poorly tolerated due to the higher dosing required to overcome its low oral bioavailability,[26] its foul taste and odor, and a higher incidence of adverse effects when taken orally, particularly nausea and vomiting. Prior pharmacokinetic studies of acetylcysteine did not consider acetylation as a reason for the low bioavailability of acetylcysteine.[27] Oral acetylcysteine is identical in bioavailability to cysteine precursors.[27] However, 3% to 6% of people given intravenous acetylcysteine show a severe, anaphylaxis-like allergic reaction, which may include extreme breathing difficulty (due to bronchospasm), a decrease in blood pressure, rash, angioedema, and sometimes also nausea and vomiting.[28] Repeated doses of intravenous acetylcysteine will cause these allergic reactions to progressively worsen in these people.

Several studies have found this anaphylaxis-like reaction to occur more often in people given intravenous acetylcysteine despite serum levels of paracetamol not high enough to be considered toxic.[29][30][31][32]

Mucolytic agent

[edit]

Acetylcysteine exhibits mucolytic properties, meaning it reduces the viscosity and adhesiveness of mucus. This therapeutic effect is achieved through the cleavage of disulfide bonds[33] within mucoproteins (strongly cross-linked mucins),[34] thereby decreasing the mucus viscosity and facilitating its clearance from the respiratory tract. This mechanism is particularly beneficial in conditions characterized by excessive or thickened mucus,[35] such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, rhinitis or sinusitis.[36] Acetylcysteine can be administered as a part of a complex molecule, thiamphenicol glycinate acetylcysteine, which also contains thiamphenicol, an antibiotic.[37]

Lungs
[edit]

Inhaled acetylcysteine has been used for mucolytic therapy in addition to other therapies in respiratory conditions with excessive and/or thick mucus production. It is also used post-operatively, as a diagnostic aid, and in tracheotomy care. It may be considered ineffective in cystic fibrosis.[38] A 2013 Cochrane review in cystic fibrosis found no evidence of benefit.[39]

Acetylcysteine is used in the treatment of obstructive lung disease as an adjuvant treatment.[40][41][42]

Other uses

[edit]

Acetylcysteine has been used to complex palladium, to help it dissolve in water. This helps to remove palladium from drugs or precursors synthesized by palladium-catalyzed coupling reactions.[43] N-acetylcysteine can be used to protect the liver.[44]

Microbiological use

[edit]

Acetylcysteine can be used in Petroff's method of liquefaction and decontamination of sputum, in preparation for recovery of mycobacterium.[45] It also displays significant antiviral activity against influenza A viruses.[46]

Acetylcysteine has bactericidal properties and breaks down bacterial biofilms of clinically relevant pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecalis, Enterobacter cloacae, Staphylococcus epidermidis, and Klebsiella pneumoniae.[47]

Side effects

[edit]
"SNOAC" redirects here. For the gene, see snoaC.

The most commonly reported adverse effects for I.V. formulations of acetylcysteine are rash, urticaria, and itchiness.[6]

Adverse effects for inhalational formulations of acetylcysteine include nausea, vomiting, stomatitis, fever, rhinorrhea, drowsiness, clamminess, chest tightness, and bronchoconstriction. Although infrequent, bronchospasm has been reported to occur unpredictably in some patients.[48]

Adverse effects for oral formulations of acetylcysteine have been reported to include nausea, vomiting, rash, and fever.[48]

Large doses in a mouse model showed that acetylcysteine could potentially cause damage to the heart and lungs.[49] They found that acetylcysteine was metabolized to S-nitroso-N-acetylcysteine (SNOAC), which increased blood pressure in the lungs and right ventricle of the heart (pulmonary artery hypertension) in mice treated with acetylcysteine. The effect was similar to that observed following a 3-week exposure to an oxygen-deprived environment (chronic hypoxia). The authors also found that SNOAC induced a hypoxia-like response in the expression of several important genes both in vitro and in vivo. The implications of these findings for long-term treatment with acetylcysteine have not yet been investigated. The dose used by Palmer and colleagues was dramatically higher than that used in humans, the equivalent of about 20 grams per day.[49] In humans, much lower dosages (600 mg per day) have been observed to counteract some age-related decline in the hypoxic ventilatory response as tested by inducing prolonged hypoxia.[50]

Although N-acetylcysteine prevented liver damage in mice when taken before alcohol, when taken four hours after alcohol it made liver damage worse in a dose-dependent fashion.[51]

Pharmacology

[edit]

Pharmacodynamics

[edit]

Acetylcysteine serves as a prodrug to L-cysteine, a precursor to the biologic antioxidant glutathione. Hence administration of acetylcysteine replenishes glutathione stores.[52]

Acetylcysteine also serves as a precursor to cystine, which in turn serves as a substrate for the cystine-glutamate antiporter on astrocytes; hence there is increasing glutamate release into the extracellular space. This glutamate in turn acts on mGluR2/3 receptors, and at higher doses of acetylcysteine, mGluR5.[58][59] Acetylcysteine may have other biological functions in the brain, such as the modulation of dopamine release and the reduction in inflammatory cytokine formation possibly via inhibiting NF-κB and modulating cytokine synthesis.[56] These properties, along with the reduction of oxidative stress and the re-establishment of glutamatergic balance, would lead to an increase in growth factors, such as brain-derived neurotrophic factor (BDNF), and the regulation of neuronal cell death through B-cell lymphoma 2 expression (BLC-2).[60]

As mentioned before, actylcysteine clears mucus by opening disulfide bonds.[33]

Pharmacokinetics

[edit]

The oral bioavailability of acetylcysteine is relatively low due to extensive first-pass metabolism in the gut wall and liver. It ranges between 6% and 10%.

Intravenous administration of acetylcysteine bypasses the first-pass metabolism, resulting in higher bioavailability compared to oral administration. Intravenous administration of acetylcysteine ensures nearly 100% bioavailability as it directly enters the bloodstream.

Acetylcysteine is extensively liver metabolized, CYP450 minimal, urine excretion is 22–30% with a half-life of 5.6 hours in adults and 11 hours in newborns.[medical citation needed]

Acetylcysteine is the N-acetyl derivative of the amino acid L-cysteine, and is a precursor in the formation of the antioxidant glutathione in the body. The thiol (sulfhydryl) group confers antioxidant effects and is able to reduce free radicals.

Chemistry

[edit]

Pure acetylcysteine is in a solid state at room temperature, appearing as a white crystalline powder or granules.[61] The solid form of acetylcysteine is stable under normal conditions, but it can undergo oxidation if exposed to air or moisture over time, leading to the formation of its dimeric form, diacetylcysteine, which can have different properties.[62] Acetylcysteine is highly hygroscopic, i.e., it absorbs moisture if exposed to open air.[61]

Acetylcysteine can sometimes appear as a light yellow cast powder instead of pure white due to oxidation. The sulfur-containing amino acids, like cysteine, are more easily oxidized than other amino acids. When exposed to air or moisture, acetylcysteine can oxidize, leading to a slight yellowish tint.[61]

Acetylcysteine in a form of a white or white with light yellow cast powder has a pKa of 9.5 at 30 °C.[12]

N-acetyl-L-cysteine is soluble in water and alcohol, and practically insoluble in chloroform and ether.[63]

Acetylcysteine dissolves readily in water, forming a colorless solution. The pH of a 1% acetylcysteine solution in water typically ranges between 2.0 and 2.8.[64] Solutions with higher concentrations of acetylcysteine have lower pH. Aqueous solutions of acetylcysteine are compatible with 0.9% sodium chloride solution; compatibility with 5% and 10% glucose solutions is also good.[61]

As for photochemical stability, acetylcysteine in dry powder form is relatively stable and does not degrade quickly when exposed to light, but in aqueous solution, acetylcysteine can degrade when exposed to sunlight. In addition, acetylcysteine in aqueous solution can undergo hydrolysis, leading to the breakdown of the amide bond in the molecule. Still, aqueous solutions of acetylcysteine are generally stable when stored properly: the solutions should be kept in tightly sealed containers and stored at controlled room temperature to prolong the stability.[65][61]

Acetylcysteine has been reported to have a pH of 2.2 when administered through inhalation.[66]

Society and culture

[edit]
Acetylcysteine capsules sold by the supplement company Life Extension
Over-the-counter (OTC) Acetylcysteine pills in China, with brand name Fluimucil

Acetylcysteine was first studied as a drug in 1963. Amazon removed acetylcysteine for sale in the US in 2021, due to claims by the Food and Drug Administration (FDA) of it being classified as a drug rather than a supplement.[67][68][69][70] In April 2022, the FDA released draft guidance on its policy regarding products labeled as dietary supplements that contain N-acetyl-L-cysteine.[71] Amazon subsequently re-listed NAC products as of August 2022.[72]

Research

[edit]

Acetylcysteine is under preliminary research for its potential to treat androgenetic alopecia (male baldness), with or without adjacent treatments such as with minoxidil.[73] Acetylcysteine may have otoprotective properties and could be useful for preventing hearing loss and tinnitus in some cases.[74][75]

Acetylcysteine may be an adjunct therapy for the treatment of addiction to cocaine, nicotine, alcohol, and other drugs.[76]

Psychiatry

[edit]

Acetylcysteine has been studied for major psychiatric disorders,[77][60][56][78] including bipolar disorder,[77] major depressive disorder, and schizophrenia.[60][56]

Preliminary research indicates N-acetylcysteine may be useful in treating obsessive-compulsive disorder,[79] specific drug addictions (cocaine), drug-induced neuropathy, trichotillomania, excoriation disorder, and a certain form of epilepsy (progressive myoclonic).[60][56][80] Other research has tested N-acetylcysteine in anxiety disorder, attention deficit hyperactivity disorder and mild traumatic brain injury, although further studies are required.[80][81]

Addiction

[edit]

Evidence to date does not support the efficacy for N-acetylcysteine in treating addictions to gambling, methamphetamine, or nicotine.[80]

Bipolar disorder

[edit]

In bipolar disorder, N-acetylcysteine has been repurposed as an augmentation strategy for depressive episodes in light of the possible role of inflammation in the pathogenesis of mood disorders. Nonetheless, meta-analytic evidence shows that add-on N-acetylcysteine was more effective than placebo only in reducing depression scales scores (low quality evidence), without positive effects on response and remission outcomes, limiting its possible role in clinical practice to date.[77][82]

COVID-19

[edit]

Acetylcysteine has been studied as a possible treatment for COVID-19, but has not improved patient outcomes by common measures.[83]

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Acetylcysteine

View on Grokipedia
from Grokipedia
Acetylcysteine, also known as N-acetylcysteine (NAC), is a synthetic derivative of the L- approved as a pharmaceutical agent primarily for its mucolytic properties in treating respiratory conditions characterized by viscous and as the standard for acetaminophen () overdose to prevent . Its involves deacetylating to , which replenishes intracellular stores—a critical depleted by acetaminophen's toxic N-acetyl-p-benzoquinone ()—and breaking bonds in mucoproteins to reduce and facilitate expectoration. Initially developed and introduced in the early 1960s as a mucolytic for conditions like chronic and , acetylcysteine's efficacy as an acetaminophen was established in the 1970s through clinical observations of reduced liver damage when administered promptly post-overdose, leading to its widespread adoption and inclusion on the World Health Organization's List of Essential Medicines. While its core indications are well-supported by empirical data from randomized trials and pharmacokinetic studies, NAC has garnered attention for potential off-label applications in mitigating oxidative stress in psychiatric disorders, neurodegenerative diseases, and contrast-induced nephropathy, though evidence for these remains mixed and requires further rigorous validation beyond preliminary and effects observed and small cohorts.

History

Discovery and Early Development

N-acetylcysteine (NAC), the N-acetyl derivative of L-cysteine, was developed in the early 1960s by researchers at & Company as a mucolytic agent to address viscous in respiratory conditions. Aaron L. Sheffner, a at the company, invented compositions utilizing N-acylated sulfhydryl compounds, including NAC, which cleave bonds in mucoproteins to reduce ; this was patented in 1960 with U.S. Patent 3,091,569 granted on June 25, 1963. In vitro studies by Sheffner demonstrated NAC's ability to lower the viscosity of mucoprotein solutions through sulfhydryl-mediated reduction of linkages. Preclinical evaluations confirmed NAC's mechanism, with W.R. Webb reporting in 1962 that it liquefies lung mucus via disulfide bond disruption in animal models. Metabolic studies by Sheffner and colleagues in 1966 further characterized NAC's rapid deacetylation to in vivo, supporting its for therapeutic use. These findings established NAC's foundational role as a targeted mucolytic, distinct from earlier agents like that risked tissue irritation. The U.S. approved NAC for clinical inhalation on September 14, 1963, initially under the trade name Mucomyst for adjunctive therapy in conditions involving thick bronchial secretions, such as acute and chronic bronchopulmonary diseases. Early adoption focused on nebulized administration to patients with , , and , where it proved effective in facilitating expectoration without significant toxicity in initial trials. This marked NAC's entry into pulmonary , predating its recognition for acetaminophen in the 1970s.

Evolution of Clinical Applications

Acetylcysteine, initially developed as a mucolytic agent, received U.S. (FDA) approval on September 14, 1963, for breaking down viscous in respiratory conditions by cleaving bonds in mucoproteins. Its early clinical applications focused on pulmonary disorders, such as chronic bronchitis and , where nebulized or oral forms facilitated clearance and improved airway patency. By 1967, reports documented its use for prophylaxis against meconium equivalent in patients, and by 1969, oral administration was employed to alleviate associated with viscous intestinal contents in the same population. The recognition of acetylcysteine's role as an antidote for acetaminophen (paracetamol) overdose marked a pivotal expansion in the 1970s, driven by increasing reports of hepatotoxicity following paracetamol poisoning, first noted in 1966. Animal studies in the early 1970s identified sulfhydryl donors like acetylcysteine as effective in replenishing depleted glutathione, a key mechanism countering acetaminophen-induced liver damage; human trials soon followed in Edinburgh, demonstrating reduced hepatotoxicity. A landmark 1977 study by Prescott et al. confirmed its efficacy in treating overdose patients, leading to standardized intravenous regimens by 1979 (300 mg/kg loading dose followed by maintenance infusions). By 1980, acetylcysteine was established as the optimal antidote, with FDA approval for oral use in acetaminophen overdose granted on January 31, 1985. Subsequent refinements included intravenous formulations, such as Acetadote approved by the FDA in 2004, which addressed limitations of like in overdose patients and improved . These developments solidified acetylcysteine's dual role in mucolytic therapy and acute , with protocols evolving to emphasize early intervention—near 100% effective if administered within 8 hours of for acetaminophen cases. Over decades, its applications remained anchored in these indications, informed by mechanistic insights into and precursor effects, though off-label explorations emerged later.

Medical Uses

Antidote for Acetaminophen Overdose

Acetylcysteine, also known as N-acetylcysteine (NAC), serves as the standard for acetaminophen () overdose, with FDA approval for treating potentially hepatotoxic doses exceeding 150 mg/kg in adults or 75-150 mg/kg in children, depending on risk factors such as chronic alcohol use or . It is nearly 100% effective in preventing when initiated within 8 hours of ingestion, significantly reducing the risk of even in delayed presentations. Clinical guidelines from bodies like the American College of Emergency Physicians endorse its use for acute single ingestions where serum acetaminophen levels plot above the treatment line on the Rumack-Matthew . The mechanism of acetaminophen toxicity involves metabolism producing the reactive intermediate , which normally conjugates with for detoxification but accumulates and binds to hepatic proteins in overdose, causing and centrilobular . Acetylcysteine addresses this by acting as a sulfhydryl donor and precursor, replenishing depleted stores to neutralize ; it also exhibits direct effects and may enhance non-toxic conjugation pathways. This causal intervention targets the core depletion of endogenous defenses, as evidenced by animal models and human pharmacokinetic studies showing restored levels correlating with prevented elevations. Intravenous administration is preferred over oral due to faster onset, better tolerability amid , and avoidance of first-pass issues, with regimens standardized to 21 or 48 hours based on severity. The FDA-approved 21-hour IV protocol consists of a of 150 mg/kg over 1 hour, followed by 50 mg/kg over 4 hours, and 100 mg/kg over 16 hours, continued until acetaminophen levels normalize and liver function improves (e.g., ALT <1,000 IU/L). For massive overdoses (>30 g in adults), extended infusions up to 48-72 hours may be required if persists, as shorter durations risk rebound in some cases. Oral dosing (140 mg/kg loading, then 70 mg/kg every 4 hours for 17 doses) remains an alternative when IV is unavailable, though efficacy drops if delayed beyond 10 hours. Efficacy data from prospective trials and meta-analyses confirm acetylcysteine's role in averting and death; a 2006 Cochrane review of randomized controlled trials found it superior to supportive care alone in reducing , with odds ratios for near zero when given early. In non-randomized studies of over 10,000 patients, treatment within 8-10 hours yielded rates under 5%, versus 40-60% untreated; even at 15-24 hours post-ingestion, it halved mortality in cases by mitigating progression to . Monitoring includes serial acetaminophen levels (detectable up to 4 hours post-ingestion), prothrombin time/INR, and ALT/AST, with discontinuation guided by normalization rather than fixed duration to optimize outcomes. Adjunctive therapies like activated (if within 1-2 hours) enhance elimination but do not supplant acetylcysteine.

Mucolytic Therapy in Respiratory Disorders

Acetylcysteine functions as a mucolytic agent by hydrolyzing disulfide bonds in mucus glycoproteins, thereby reducing mucus viscosity and facilitating expectoration and clearance from the airways. This action is particularly relevant in hypersecretory respiratory conditions where thickened mucus impairs mucociliary clearance. In addition to its mucolytic effects, acetylcysteine exhibits antioxidant properties that may mitigate oxidative stress in inflamed airways, though its primary benefit in respiratory therapy stems from viscosity reduction rather than anti-inflammatory mechanisms alone. In (COPD) and chronic bronchitis, oral acetylcysteine at doses of 600 mg daily has been associated with reduced frequency of acute s and improved symptom control in multiple randomized trials, with meta-analyses confirming a significant decrease in patients experiencing at least one exacerbation over 3–6 months compared to . However, a 2024 multicenter trial involving high-dose (1200 mg daily) therapy in stable COPD patients found no significant reduction in annual exacerbation rates or improvements in lung function metrics such as forced expiratory volume in one second (FEV1). Nebulized acetylcysteine has shown efficacy in liquefying in COPD, with one 2024 study reporting improved clearance and reduced exacerbation risk when administered alongside standard bronchodilators. For , acetylcysteine reduces sputum viscosity by disrupting disulfide linkages, aiding pulmonary secretion removal, though clinical trials indicate benefits are more pronounced when combined with other therapies like rather than as monotherapy. In acute or post-infective , systematic reviews suggest nebulized or oral forms may enhance symptom resolution and lung function (e.g., FEV1 improvements), but evidence remains limited by small sample sizes and heterogeneity in protocols. Administration for mucolytic purposes typically involves nebulization of 3–5 mL of 20% solution or 6–10 mL of 10% solution every 2–6 hours for acute settings, diluted if risk is high; oral dosing for chronic prophylaxis is 600 mg daily, with higher doses (up to 1200 mg) tolerated in respiratory patients per safety data from long-term studies. Inhaled forms require careful monitoring for transient , which occurs in up to 20% of initial treatments but diminishes with continued use or pre-treatment with bronchodilators. Overall, while acetylcysteine's mucolytic role is mechanistically sound and supported for adjunctive use in select hypersecretory disorders, its impact on hard outcomes like hospitalization rates varies, underscoring the need for individualized application based on burden and profile.

Other Established Indications

Acetylcysteine has been employed prophylactically to mitigate contrast-induced nephropathy (CIN), a form of following intravascular administration of media, particularly in high-risk patients with preexisting renal impairment. Multiple meta-analyses of randomized controlled trials indicate a reduction in CIN incidence with acetylcysteine supplementation, with one analysis of 101 trials reporting an of 0.74 for CIN prevention compared to controls (95% CI 0.66-0.83). Another graded the evidence as moderate quality, showing an of 0.72 (95% CI 0.65-0.79) for decreased CIN risk. However, mechanistic studies have questioned its direct renal protective effects, attributing benefits potentially to hydration protocols rather than acetylcysteine's properties, and clinical guidelines do not universally endorse it as standard care due to inconsistent trial outcomes. Topical acetylcysteine eye drops (typically 5-10% solutions) are established for treating , filamentary , and conditions involving viscous ocular or , with approvals in regions including the and . These formulations reduce viscosity and by breaking bonds in mucins, improving tear film stability and symptom relief when used 3-4 times daily. Clinical applications demonstrate efficacy in corneal and management, though not FDA-approved for ophthalmic use . from trials supports its role in moderate-to-severe dry eye, with reduced ocular surface observed in patients unresponsive to standard lubricants. Acetylcysteine is used as an adjunct in severe alcoholic hepatitis to reduce oxidative stress by replenishing glutathione stores, potentially improving short-term survival outcomes when combined with glucocorticoids. A randomized controlled trial demonstrated enhanced 1-month survival with this combination therapy compared to glucocorticoids alone. In , beyond general mucolytic effects in respiratory disorders, high-dose oral acetylcysteine (up to 2,700 mg daily) has shown benefits in modulating and , with studies reporting improved function parameters like forced expiratory volume in 1 second (FEV1) after long-term administration. further aids in sputum clearance and biofilm disruption, contributing to better pulmonary toilet, though it does not consistently alter sputum markers. These applications leverage acetylcysteine's glutathione precursor role to counter imbalances inherent to the disease.

Investigational and Off-Label Applications

Psychiatric and Addiction Treatment

N-acetylcysteine (NAC) has been investigated as an adjunctive therapy in various psychiatric disorders and compulsive behaviors due to its ability to modulate glutamatergic transmission via the cystine-glutamate exchanger and replenish to combat , which are implicated in conditions like and obsessive-compulsive disorder (OCD). In , meta-analyses of randomized controlled trials indicate that adjunctive NAC improves negative symptoms, such as social withdrawal and blunted affect, with doses typically ranging from 1,200 to 2,400 mg daily over 8-24 weeks, though effects on positive symptoms or cognition remain inconsistent. For OCD, systematic reviews support NAC as an augmentation to selective serotonin reuptake inhibitors (SSRIs), particularly in moderate to severe cases, with trials showing reductions in Yale-Brown Obsessive Compulsive Scale scores by 20-35% at doses of 2,000-3,000 mg daily for 12 weeks, attributed to glutamate normalization in cortico-striatal circuits. This glutamatergic mechanism also underlies NAC's exploration in OCD-related compulsive behaviors, such as trichotillomania, where a randomized placebo-controlled trial reported significant symptom reductions at 1,200-2,400 mg daily, and in binge eating disorder, with preclinical rodent models and exploratory human studies showing decreased binge episodes via restored glutamate homeostasis. Evidence for depressive symptoms is mixed, with some meta-analyses reporting modest improvements in Hamilton Depression Rating Scale scores and functionality when added to antidepressants, but others finding no superiority over in . Adjunctive NAC shows limited efficacy in , failing to significantly alter depressive or manic episodes in controlled trials. In addiction treatment, NAC targets cue-induced craving by restoring extracellular glutamate levels and reducing compulsive drug-seeking behaviors in preclinical models, with clinical evidence strongest for dependence, where randomized s demonstrate decreased craving intensity, cocaine-cue reactivity, and self-reported desire to use at 2,400-3,600 mg daily. Meta-analyses of substance use disorders confirm NAC's role in attenuating cravings across , , and , though effect sizes are small to moderate and benefits are not sustained without behavioral interventions. Results are negative for dependence, showing no reduction in use, craving, or withdrawal severity in a 2021 randomized . For alcohol use disorder, NAC has been investigated for modulating glutamate and reducing cravings and withdrawal symptoms via oxidative stress mitigation, but clinical trials show mixed results with limited efficacy in reducing consumption. Regarding alcohol-induced hangover prevention, no established evidence-based protocol exists, as randomized trials indicate ineffectiveness overall. One study administered 600-1800 mg NAC post-alcohol consumption after reaching target intoxication, showing no significant overall reduction in hangover symptoms (possible subgroup benefit in females only). Another used 1.2 g pretreatment before drinking plus 1.2 g post-drinking, with no effect on symptoms or biomarkers. Popular anecdotal recommendations of 600-1800 mg pretreatment 30-60 minutes before drinking lack scientific support. For youth , NAC lacks efficacy as monotherapy, per a 2025 double-blind study, but may enhance outcomes when combined with . Overall, while promising for craving reduction, larger s are needed to establish NAC's standalone therapeutic value in , given heterogeneous study designs and dropout rates up to 30%.

Neurological and Metabolic Conditions

N-acetylcysteine (NAC) has been studied for its potential neuroprotective effects in various neurodegenerative disorders, primarily through its role in replenishing , a key depleted in conditions like (PD) and (AD). In PD models, NAC demonstrates mitigation of and dopaminergic neuron loss, suggesting preclinical . Clinical trials, such as a phase I study completed in 2013, have explored oral NAC to address brain glutathione deficits in early PD patients via magnetic resonance , showing preliminary safety but requiring further efficacy data from larger cohorts. Similarly, in AD, formulations containing NAC have yielded modest cognitive improvements in small trials, attributed to reduced oxidative damage, though standalone NAC evidence remains limited and inconsistent. For psychiatric conditions with neurological underpinnings, adjunctive NAC at doses of 1-2 g/day has shown efficacy in , improving negative symptoms and total scores in meta-analyses of randomized trials, potentially via glutamate modulation and effects. In obsessive-compulsive disorder (OCD), a 2024 meta-analysis of trials indicated NAC augmentation reduces moderate-to-severe symptoms, with effect sizes favoring doses around 2-3 g/day, though heterogeneity in study designs warrants caution. Evidence for traumatic brain injury (TBI) includes adjunctive NAC reducing oxidative markers and supporting recovery in preclinical and early , but phase II trials highlight challenges with and need for probenecid co-administration to enhance brain penetration. Preliminary evidence from a small randomized sham-controlled pilot study (n=35) suggests that NAC in combination with vitamins E and C (600 mg NAC twice daily) may reduce migraine frequency, intensity, and duration in adults, potentially through antioxidant effects enhancing glutathione and modulating glutamate activity; however, evidence for NAC monotherapy is limited, and larger trials are needed for validation. In metabolic conditions, NAC supplementation improves insulin sensitivity and lipid profiles in (PCOS), with a 2023 meta-analysis of trials showing significant reductions in fasting insulin, HOMA-IR, and testosterone at 1.8 g/day doses, often outperforming or complementing metformin. For (MetS), 12-week administration of 1.8 g/day NAC enhanced glycemic control, HDL-cholesterol, and inflammatory markers like hs-CRP in randomized studies of subjects. In diabetic , high-dose NAC (1.2-1.8 g/day) over 8-12 weeks reduced pain scores and improved quality-of-life measures in a 2025 trial, linking benefits to antioxidant restoration amid hyperglycemia-induced . These metabolic effects stem from NAC's donation boosting synthesis, countering in insulin-resistant states, though long-term outcomes and optimal dosing require confirmation from larger, prospective studies.

Respiratory and Infectious Disease Research

N-acetylcysteine (NAC) has been investigated for its potential roles in modulating , , and immune responses in chronic respiratory conditions beyond its established mucolytic applications, such as in (COPD) and (IPF). High-dose oral NAC (up to 1800 mg daily) has shown safety in long-term use for these diseases, with preclinical and small clinical studies indicating reduced oxidative damage to lung tissue via replenishment of levels and inhibition of pro-inflammatory cytokines like TNF-α and IL-6. A 2021 review highlighted NAC's ability to decrease exacerbation rates in COPD by 20-30% in some cohorts, though larger randomized controlled trials (RCTs) are needed to confirm efficacy independent of mucolytic benefits. In infectious respiratory diseases, NAC's antibiofilm properties have garnered attention for combating bacterial persistence in conditions like and , where pathogens such as and form protective s resistant to s. studies demonstrate that NAC concentrations of 10-15 mM disrupt matrices by breaking bonds in extracellular polymeric substances, enhancing penetration and reducing bacterial viability by up to 90% against clinical isolates. Clinical observations from 2018 onward suggest adjunctive nebulized NAC (300-600 mg) improves outcomes in infections, a common opportunistic in immunocompromised respiratory patients, by exhibiting direct effects at MIC values of 8-16 mg/mL. Recent 2025 research further confirmed NAC's inhibition of (NETs) and s in , a cause of , supporting its potential in tropical respiratory infections. For viral respiratory infections, NAC's antiviral mechanisms— including glutathione-mediated redox modulation and (TLR7) activation leading to type I production—have been explored in , (RSV), and SARS-CoV-2. In RSV models, NAC at 5-10 mM protected airway epithelial cells, suppressed mucin hypersecretion, and exerted anti-inflammatory effects during infection, reducing viral replication . trials from 2020-2024 produced conflicting results: retrospective cohorts (n=465) reported 40-50% lower rates and mortality with intravenous NAC (150 mg/kg loading dose followed by maintenance), attributed to reduced . However, a 2024 RCT (n=200) found no significant differences in clinical outcomes like hospitalization duration or oxygen needs with oral NAC adjunct therapy, cautioning against routine use without further validation. Ongoing phase II trials as of 2025 continue to assess NAC's role in post-viral sequelae and prevention, emphasizing its low-risk profile for adjunctive therapy in high-oxidative-stress infections.

Adverse Effects and Safety Profile

Common Side Effects

When administered orally, particularly in high doses for acetaminophen overdose, acetylcysteine frequently induces gastrointestinal side effects including , , and , affecting up to 30-50% of patients in clinical settings. These effects stem from the drug's direct irritant action on the and its sulfurous odor, which can exacerbate emesis; incidence decreases with lower chronic doses under 3,000 mg daily. Stomach upset and epigastric pain are also reported, often resolving with dose adjustment or administration with . Intravenous acetylcysteine commonly provokes mild reactions such as , pruritus, and urticaria, occurring in approximately 10-20% of infusions, alongside and similar to oral routes. Headaches, including potentially migraine-like symptoms, are a recognized side effect, particularly with higher doses for acetaminophen overdose or in sensitive individuals; clinical studies indicate increased headache risk with intravenous administration, often dose-dependent and resolving with reduction or discontinuation. These cutaneous effects are typically anaphylactoid rather than IgE-mediated, linked to rapid infusion rates and release, and can be mitigated by slowing administration or with antihistamines. For nebulized or inhaled formulations used as mucolytics, common side effects include increased coughing due to enhanced mucus liquefaction, , , and transient , observed in over 10% of users. Fever and drowsiness may accompany these, particularly in pediatric or respiratory-compromised patients, but most resolve upon discontinuation. Across routes, acetylcysteine is generally well-tolerated at therapeutic doses, with gastrointestinal complaints predominating and rarely necessitating cessation; however, patient-specific factors like concurrent illness amplify risks.

Serious Risks and Contraindications

Intravenous administration of acetylcysteine carries a risk of anaphylactoid reactions, occurring in 3.7% to 44% of cases depending on infusion protocols and definitions, with symptoms including flushing, rash, urticaria, pruritus, angioedema, hypotension, tachycardia, and bronchospasm. These reactions are non-IgE-mediated, often histamine-driven, and most frequently arise during the initial loading dose, potentially resolving with antihistamines or temporary infusion cessation but occasionally requiring epinephrine in severe instances. Rare fatalities have been reported, such as myocardial infarction following an anaphylactoid episode in acetaminophen overdose treatment. Inhalation of nebulized acetylcysteine can provoke , wheezing, and chest tightness, particularly in patients with or bronchial reactivity, necessitating caution or premedication with bronchodilators. High-volume intravenous infusions risk fluid overload, potentially causing and seizures, especially in vulnerable populations like children or those with renal impairment. Contraindications include to acetylcysteine or its components, with prior anaphylactoid reactions precluding further intravenous use. Acute represents a contraindication for inhaled forms due to heightened bronchospastic risk. Oral administration for acetaminophen overdose lacks absolute s beyond , though clinical judgment is advised in cases of active or gastrointestinal obstruction.

Drug Interactions

Acetylcysteine exhibits limited clinically significant drug interactions, primarily due to its role as a glutathione precursor and mucolytic agent, though compatibility with other drugs during intravenous administration remains unestablished. A moderate interaction occurs with , where coadministration potentiates vasodilatory effects, potentially causing symptomatic and exacerbated nitroglycerin-induced headaches, as observed in patients with . This arises from acetylcysteine's sulfhydryl donation enhancing nitroglycerin's biotransformation to . Activated interferes with oral acetylcysteine absorption in acetaminophen overdose scenarios, reducing , while acetylcysteine diminishes charcoal's adsorptive capacity for acetaminophen and coingestants. Coadministration should thus be avoided or timed separately, with caution advised. Minor interactions include reduced efficacy with certain heavy metal compounds like auranofin or salts, due to sulfhydryl binding, though clinical relevance is low. Overall, acetylcysteine's profile supports broad compatibility, with monitoring recommended in .

Pharmacology

Pharmacodynamics

Acetylcysteine acts primarily as a mucolytic agent by virtue of its free sulfhydryl (-SH) group, which cleaves bonds (-S-S-) in the glycoproteins of , depolymerizing oligomers and thereby decreasing to enhance clearance from airways. This mechanism facilitates expectoration in conditions of excessive production, such as or , with effects observable within 5-10 minutes of nebulized administration at concentrations of 10-20%. The reduction in elasticity and adhesiveness is dose-dependent, with higher concentrations (e.g., 20% solutions) more effectively disrupting high-molecular-weight compared to lower ones. In acetaminophen () overdose, acetylcysteine functions as a glutathione precursor, supplying to replenish depleted hepatic stores that normally conjugate the toxic N-acetyl-p-benzoquinone imine (), preventing its covalent binding to cellular proteins and subsequent oxidative . Intravenous regimens, such as the 21-hour protocol delivering 150 mg/kg followed by maintenance infusions, restore glutathione levels within hours, reducing the risk of fulminant hepatic failure when initiated within 8-16 hours post-ingestion. This sulfhydryl donation also directly scavenges , though resynthesis predominates as the key protective pathway. Beyond these primary actions, acetylcysteine demonstrates effects by scavenging (e.g., , hydroxyl radicals) via its group and supporting endogenous activity, which mitigates in various tissues. It may also modulate inflammation by inhibiting nuclear factor-kappa B activation and release, though these effects are secondary to its core biochemical interactions.

Pharmacokinetics

Acetylcysteine exhibits route-dependent pharmacokinetics, with subject to significant first-pass leading to low systemic of approximately 6–10%, while intravenous administration achieves nearly complete . Taking oral NAC with food, including carbohydrate-containing meals, can further reduce its bioavailability and peak plasma concentrations, though no unique effect from carbohydrates separate from general food effects has been identified; it is recommended to take NAC on an empty stomach for optimal absorption. Following oral doses of 200–400 mg, peak plasma concentrations range from 0.35 to 4 mg/L, attained within 1–2 hours, reflecting rapid gastrointestinal absorption despite incomplete systemic exposure. Intravenous dosing bypasses these limitations, enabling higher and more predictable plasma levels for acute applications such as acetaminophen overdose. Distribution occurs widely, with a steady-state of about 0.47 L/kg following intravenous administration, indicating moderate tissue penetration. varies between 50% and 83%, potentially influencing free availability. Metabolism primarily occurs in the liver via deacetylation to by enzymes such as aminoacylase 1, followed by further oxidation to cystine or incorporation into synthesis; extensive first-pass effects in the gut and liver contribute to the low oral . Hepatic processing also yields and conjugates. Excretion is predominantly renal, with 13–38% of an oral radiolabeled dose recovered in over 24 hours and approximately 30% overall urinary elimination of metabolites; fecal accounts for about 3%. The elimination is approximately 5.6 hours, supporting dosing intervals in clinical protocols.

Chemistry and Formulation

Chemical Structure and Synthesis

Acetylcysteine, systematically named (2R)-2-acetamido-3-sulfanylpropanoic acid, is the N-acetyl derivative of the L-. Its molecular formula is C5H9NO3S, with a molecular weight of 163.19 g/mol. The structure features a chiral α-carbon (C2) bearing an acetamido group (-NHCOCH3), a (-COOH) at C1, and a (-SH) side chain at C3 on a backbone, which imparts reducing and mucolytic properties. Acetylcysteine is synthesized primarily through of L-cysteine or its oxidized dimer L-cystine. The standard laboratory method involves reacting L-cysteine with in aqueous or basic conditions to form the N-acetyl product, followed by acidification and for purification. Industrially, production often begins with L-cystine, which is acetylated to N,N'-diacetyl-L-cystine using , then reduced electrochemically or chemically to yield acetylcysteine while preventing oxidation to the . This approach leverages the stability of cystine as a starting , with yields optimized through controls to minimize dimer formation. Recent green methods incorporate for salt removal and carbon electrodes for reduction, enhancing .

Pharmaceutical Preparations

Acetylcysteine is formulated for oral, intravenous, and administration to accommodate its uses as a mucolytic agent and for acetaminophen overdose. Oral preparations include solutions, effervescent tablets, and powder packets, often requiring dilution to improve tolerability due to gastrointestinal side effects. Effervescent tablets, such as CETYLEV, are available in strengths of 500 mg, 1 g, and 2.5 g, dissolved in prior to for acetaminophen treatment. Tablets and powders, typically 100 mg or 200 mg doses, are used for mucolytic purposes and administered multiple times daily. Intravenous formulations, like Acetadote, consist of a 200 mg/mL solution in 10 mL ampoules or vials, diluted in dextrose or saline for infusion over 21 hours in a of 150 mg/kg followed by maintenance doses totaling 300 mg/kg. Preparation involves aseptic dilution to concentrations of 6.25 mg/mL or as specified, with stability maintained under refrigeration for unopened vials. Inhalation preparations are sterile solutions of 10% or 20% acetylcysteine in 10 mL or 30 mL vials, such as Mucomyst, nebulized directly or instilled intratracheally, with doses of 3-5 mL of 20% or 6-10 mL of 10% solution administered 3-4 times daily. These unpreserved solutions require immediate use after opening to prevent bacterial . Branded products like Fluimucil offer effervescent granules or sachets for oral mucolytic in various global markets.

Regulatory Status and Controversies

Approval History and Global Regulations

Acetylcysteine was initially approved by the U.S. (FDA) on September 14, 1963, as an inhalation solution for mucolytic therapy in conditions involving thick secretions, such as chronic bronchopulmonary diseases. The oral solution formulation received FDA approval in 1978 specifically for treating acetaminophen overdose to prevent . Subsequent approvals expanded intravenous options, with Acetadote (acetylcysteine injection) authorized on January 23, 2004, for the same indication when oral administration is not feasible. Effervescent tablets under the brand Cetylev were approved on January 29, 2016, providing an alternative oral form for pediatric and adult use in acetaminophen poisoning. Internationally, acetylcysteine entered medical use in the late following its initial development as a mucolytic agent, with approvals granted by authorities in multiple countries for respiratory and applications by the 1970s. In the , it holds marketing authorizations through national procedures rather than centralized EMA approval, permitting its use for mucolytic effects in acute and chronic respiratory disorders as well as for paracetamol overdose prophylaxis. For instance, acetylcysteine solutions and effervescent forms have been authorized in countries like the since at least the early 2000s, with ongoing assessments confirming safety profiles. Acetylcysteine is included on the World Health Organization's List of Essential Medicines, reflecting its global recognition for treating and as a mucolytic, with availability in over 100 countries under various regulatory frameworks. Regulatory status varies by jurisdiction: in many nations, it is classified strictly as a for use while available over-the-counter for oral mucolytic purposes in others, such as certain European and Asian markets. No major international bans exist, though formulations must comply with local pharmacopeial standards for purity and dosing.

FDA Supplement Classification Dispute

The FDA classifies N-acetyl-L-cysteine (NAC) as excluded from the dietary supplement definition under the Dietary Supplement Health and Education Act (DSHEA) due to its approval as a new drug prior to DSHEA's October 15, 1994, enactment. NAC was approved in 1963 as a mucolytic agent, invoking the exclusionary clause in 21 U.S.C. § 321(ff)(3)(B)(i), which bars ingredients first authorized for use in a (NDA) or (IND) before that date from qualifying as dietary ingredients. Enforcement of this classification intensified in August 2020 when the FDA issued warning letters to multiple supplement manufacturers, including those marketing NAC for mitigation, deeming such products misbranded or unapproved new s because NAC's drug status precludes its lawful inclusion in dietary supplements. Industry opposition followed, with trade groups like the Natural Products Association filing lawsuits in December 2021 challenging the FDA's retroactive application of the exclusion and citing NAC's pre-1994 supplemental marketing history; some suits were withdrawn after FDA signals of flexibility. Citizen petitions in 2021 requested reconsideration, providing evidence of NAC's prior dietary use and arguing the exclusion does not apply if marketed as a supplement before drug approval, though the FDA maintained that drug approval timing controls. In a March 31, 2022, response to the petitions, the FDA upheld the exclusion, stating no evidence altered NAC's pre-DSHEA drug status, but acknowledged its long-term safety in supplemental doses with no identified risks warranting immediate action; the agency committed to exploring for potential inclusion while exercising enforcement discretion. This discretion was formalized in August guidance, permitting continued marketing of NAC products that would otherwise qualify as dietary supplements if not for the exclusion, provided they were lawfully sold before FDA's 2020 objections, adhere to current good manufacturing practices, and avoid unapproved disease claims. As of October 2025, no has reclassified NAC, preserving its excluded status amid ongoing FDA safety reviews, including a 2023 peer-reviewed literature assessment.

Ongoing Research and Future Directions

Recent Clinical Trials (2020–2025)

In the realm of psychiatric disorders, a 2024 systematic review and meta-analysis of randomized controlled trials (RCTs) evaluated N-acetylcysteine (NAC) as an augmentation therapy for moderate to severe obsessive-compulsive disorder (OCD), finding it significantly reduced Yale-Brown Obsessive Compulsive Scale scores compared to placebo, with good tolerability (standardized mean difference -0.62, 95% CI -1.04 to -0.20; 6 RCTs, n=218). A 2025 RCT of NAC for co-occurring posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) in veterans (n=106) reported no significant reduction in PTSD symptoms or alcohol consumption versus placebo over 12 weeks, though NAC was safe with minimal adverse events. Earlier, a 2020 pilot RCT (n=35) for comorbid AUD/PTSD demonstrated preliminary feasibility but required larger trials for efficacy confirmation. For neurological conditions, a 2020 multicenter RCT (n=15) tested NAC in RYR1-related congenital myopathies, showing improved muscle oxidative capacity and reduced after 6 months of treatment (600 mg twice daily), with no serious adverse effects, suggesting potential as a disease-modifying . In hereditary amyloid angiopathy, a single-center nonrandomized (published 2024) administered NAC (600 mg daily) to patients, reporting it was well-tolerated and associated with slowed disease progression via reduced cerebral microbleeds and improved cognitive scores over 2 years. A phase I in 2020 for (n=11) found oral NAC (1800 mg daily for 6 months) enhanced cone function on without altering visual fields. Amid the , multiple trials assessed NAC's antioxidant and mucolytic properties. A 2021 pilot RCT (n=40) of intravenous NAC in COVID-19-associated found no improvement in oxygenation or ventilator-free days versus standard care. A 2022 open-label RCT (n=135) of NAC spray reported reduced symptom duration and hospitalization rates in mild-moderate cases, but lacked control for definitive efficacy. A 2024 meta-analysis of NAC in severe concluded no overall benefit on mortality or recovery, attributing inconsistent prior positive signals to small sample sizes and confounding factors like concurrent therapies. In , a 2024 double-blind RCT (n=80) compared NAC (1200 mg daily) to pregabalin in painful diabetic neuropathy, yielding similar reductions in pain scores (NAC: -3.2 points on visual analog scale; pregabalin: -3.5) over 8 weeks, with NAC showing fewer side effects like dizziness. A 2021 of RCTs for (including neuropathic types) supported NAC's adjunctive role in reducing intensity via modulation, though evidence quality was moderate due to heterogeneity. For respiratory exacerbations, a 2024 double-blind RCT (n=92) in acute found NAC (600 mg thrice daily IV/oral) shortened hospital stays by 1.5 days and improved forced expiratory volume versus placebo, without increasing adverse events. In drug-induced , a 2020 RCT (n=43) of intravenous NAC reduced hospital length by 2.4 days in acetaminophen-toxic cases, though it did not accelerate normalization. A January 2025 RCT in critically ill patients noted NAC elevated antioxidant enzymes (, ) but failed to impact clinical endpoints like mortality.

Evidence Gaps and Methodological Critiques

Despite promising preclinical and early clinical data suggesting and modulatory effects, substantial evidence gaps persist regarding N-acetylcysteine (NAC)'s efficacy for off-label indications such as psychiatric disorders, neurodegenerative conditions, and viral infections like COVID-19. Systematic reviews highlight that while NAC replenishes and modulates glutamate dysregulation, human trials often fail to demonstrate consistent clinical benefits due to insufficient powering and heterogeneous protocols. For instance, in psychiatric applications, meta-analyses of adjunctive NAC for , depression, and reveal mixed outcomes, with benefits primarily in negative symptoms or craving reduction but no robust effects on core positive symptoms or remission rates in larger cohorts. A 2025 trial in youth found NAC ineffective without paired behavioral interventions like , underscoring gaps in standalone efficacy data. Methodological critiques frequently cite small sample sizes (often n<100), short durations (typically 8-12 weeks), and variability in dosing (ranging from 600 mg/day to 3 g/day orally or higher intravenously), which confound dose-response relationships and generalizability. In studies, heterogeneous craving assessment tools and self-reported outcomes introduce subjectivity , while lack of standardized glutamate biomarkers limits mechanistic validation. For , early observational and small RCTs (e.g., n=135 severely ill patients receiving 300 mg/kg IV) suggested reductions in inflammatory markers like CRP and , but subsequent analyses critique inadequate blinding, interim analyses altering endpoints, and failure to account for confounders such as concurrent steroids or ventilatory support. A 2023 RCT of oral NAC in hospitalized patients noted no significant mortality or recovery differences, attributing null results to late-stage initiation and insufficient sample powering for effects. In respiratory conditions beyond acute mucolysis, long-term high-dose NAC (e.g., 600 mg twice daily for 1 year) failed to reduce exacerbation rates or improve lung function in COPD patients in a 2024 multicenter trial (n=523), highlighting gaps in evidence for chronic supplementation amid variable baseline levels. Critiques extend to potential over-reliance on surrogate endpoints like reductions without correlating to hard outcomes (e.g., hospitalization or ), and under-exploration of pharmacokinetic interactions in settings common in psychiatric and elderly populations. Publication bias may inflate perceived benefits, as negative or null trials (e.g., for major depression at 2 g/day over 12 weeks) receive less visibility despite rigorous design. Overall, the field requires large-scale, phase III RCTs with standardized protocols, diverse demographics, and long-term follow-up to address these deficits and clarify NAC's role beyond acetaminophen overdose .

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK537183/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC8234027/
  3. https://herzenberglab.stanford.edu/sites/g/files/sbiybj27506/files/media/file/lah577_historyofnac.pdf
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC8211525/
  5. https://pubmed.ncbi.nlm.nih.gov/24080471/
  6. https://www.sciencedirect.com/science/article/pii/S0163725821001182
  7. https://patents.google.com/patent/US3091569A/en
  8. https://pubmed.ncbi.nlm.nih.gov/13977050/
  9. https://pubmed.ncbi.nlm.nih.gov/5971807/
  10. https://go.drugbank.com/drugs/DB06151
  11. https://journal.chestnet.org/article/S0012-3692%2816%2939682-9/fulltext
  12. https://pubchem.ncbi.nlm.nih.gov/compound/Acetylcysteine
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC6610312/
  14. https://www.thelancet.com/article/S0140-6736%2813%2962062-0/fulltext
  15. https://www.mdpi.com/2673-4389/5/2/20
  16. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-539_Acetadote.cfm
  17. https://emedicine.medscape.com/article/820200-treatment
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC2637612/
  19. https://www.acmt.net/wp-content/uploads/2022/06/PRS_160315_Duration-of-Intravenous-Acetylcysteine-Therapy-Following-Acetaminophen-Overdose.pdf
  20. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.828565/full
  21. https://www.ncbi.nlm.nih.gov/books/NBK441917/
  22. https://www.ncbi.nlm.nih.gov/books/NBK546019/
  23. https://www.mdpi.com/2076-3921/12/9/1713
  24. https://www.sciencedirect.com/science/article/pii/S0300289624000693
  25. https://www.sciencedirect.com/science/article/abs/pii/S0149291800884799
  26. https://publications.ersnet.org/content/errev/24/137/451
  27. https://www.nature.com/articles/s41467-024-51079-1
  28. https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-024-03243-y
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC7892733/
  30. https://bmjopen.bmj.com/content/12/3/e053625
  31. https://www.mayoclinic.org/drugs-supplements/acetylcysteine-inhalation-route/description/drg-20061456
  32. https://www.drugs.com/dosage/acetylcysteine.html
  33. https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-019-1078-y
  34. https://www.sciencedirect.com/science/article/abs/pii/S2212534524001618
  35. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793866
  36. https://pubmed.ncbi.nlm.nih.gov/37790125/
  37. https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2541
  38. https://patient.info/medicine/acetylcysteine-for-dry-eyes-ilube
  39. https://www.healthhub.sg/medication-devices-and-treatment/medications/acetylcysteine-eye-drop
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC7242486/
  41. https://pubmed.ncbi.nlm.nih.gov/22070475/
  42. https://www.pnas.org/doi/10.1073/pnas.0511304103
  43. https://www.sciencedirect.com/science/article/abs/pii/S0022347664802894
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC8879903/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC3044191/
  46. https://pubmed.ncbi.nlm.nih.gov/29457216/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC9095537/
  48. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1421150/full
  49. https://www.sciencedirect.com/science/article/abs/pii/S2211364920300506
  50. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/483113
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC11837714/
  52. https://www.psychiatrist.com/jcp/n-acetylcysteine-depressive-symptoms-functionality/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC8077050/
  54. https://www.sciencedirect.com/science/article/abs/pii/S0165178116308861
  55. https://onlinelibrary.wiley.com/doi/10.1111/adb.70001
  56. https://www.scielo.br/j/rbp/a/8G5zRRgQS5X4RxMMRnPrPVf/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC12421191/
  58. https://www.nature.com/articles/s41598-021-92676-0
  59. https://www.mdpi.com/2305-6304/12/8/585
  60. https://www.nature.com/articles/s41386-025-02061-y
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC11412889/
  62. https://www.tandfonline.com/doi/full/10.1080/17582024.2025.2563489
  63. https://clinicaltrials.gov/study/NCT01470027
  64. https://www.alzdiscovery.org/cognitive-vitality/ratings/n-acetylcysteine
  65. https://www.nature.com/articles/s41398-018-0266-8
  66. https://pubmed.ncbi.nlm.nih.gov/39376972/
  67. https://pubmed.ncbi.nlm.nih.gov/37596428/
  68. https://pubmed.ncbi.nlm.nih.gov/32306462/
  69. https://pubmed.ncbi.nlm.nih.gov/37841396/
  70. https://www.tandfonline.com/doi/full/10.1080/09513590.2024.2381498
  71. https://www.sciencedirect.com/science/article/pii/S1756464622003693
  72. https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-025-01624-9
  73. https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-024-01528-8
  74. https://www.sciencedirect.com/science/article/pii/S095461111630141X
  75. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0203941
  76. https://www.nature.com/articles/s41598-025-13506-1
  77. https://onlinelibrary.wiley.com/doi/10.1155/2022/4846336
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC10390689/
  79. https://www.sciencedirect.com/science/article/pii/S2405844024012106
  80. https://clinicaltrials.gov/study/NCT05736887
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC9651994/
  82. https://www.aafp.org/pubs/afp/issues/2009/0801/p265.html
  83. https://pubmed.ncbi.nlm.nih.gov/19280424/
  84. https://examine.com/supplements/n-acetylcysteine/
  85. https://www.mayoclinic.org/drugs-supplements/acetylcysteine-oral-route/description/drg-20311314
  86. https://pubmed.ncbi.nlm.nih.gov/20584210/
  87. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f56b4087-db48-4fd7-84ec-9c927962b805
  88. https://www.healthline.com/health/drugs/acetylcysteine-inhalation-solution
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC5962465/
  90. https://www.annemergmed.com/article/S0196-0644%2805%2901795-6/pdf
  91. https://cumming.ucalgary.ca/sites/default/files/teams/127/pearl-ofthe-week/NAC%2520anaphylactoid%2520reactions%25202019.pdf
  92. https://intjem.biomedcentral.com/articles/10.1186/1865-1380-4-54
  93. https://reference.medscape.com/drug/acetylcysteine-343425
  94. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021539s019lbl.pdf
  95. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21539_N-acetylcysteine_lbl.pdf
  96. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8d81039e-20ef-5144-e053-2a95a90a89fd&type=display
  97. https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021539s004lbl.pdf
  98. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-539_Acetadote_BioPharmr.pdf
  99. https://pubmed.ncbi.nlm.nih.gov/3127076/
  100. https://pubmed.ncbi.nlm.nih.gov/11714205/
  101. https://www.hhs.texas.gov/sites/default/files/documents/acetylcysteine-nac-monograph.pdf
  102. https://www.pediatriconcall.com/drugs/acetyl-cysteine/219
  103. https://pmc.ncbi.nlm.nih.gov/articles/PMC8719286/
  104. https://pubmed.ncbi.nlm.nih.gov/15281093/
  105. https://www.jci.org/articles/view/110853
  106. https://pubmed.ncbi.nlm.nih.gov/19821517/
  107. https://pubmed.ncbi.nlm.nih.gov/34171332/
  108. https://www.mdpi.com/1648-9144/57/11/1218
  109. https://pubmed.ncbi.nlm.nih.gov/2029805/
  110. https://www.mdpi.com/2076-3921/10/6/967
  111. https://www.sigmaaldrich.com/US/en/product/sial/a7250
  112. https://utah.ae/n-acetyl-l-cysteine-nac/
  113. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4409042
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC4540061/
  115. https://www.sciencedirect.com/science/article/abs/pii/S1383586623009942
  116. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207916s003lbl.pdf
  117. https://www.vinmec.com/eng/blog/acetylcysteine-indications-dosage-and-side-effects-en
  118. https://www.medsafe.govt.nz/profs/datasheet/a/Acetylcysteineinj.pdf
  119. https://labeling.pfizer.com/ShowLabeling.aspx?id=4101
  120. https://www.pfizermedical.com/acetylcysteine/dosage-admin
  121. https://synapse.patsnap.com/article/what-is-acetylcysteine-used-for
  122. https://pmc.ncbi.nlm.nih.gov/articles/PMC10376274/
  123. https://www.drugs.com/history/cetylev.html
  124. https://www.sciencedirect.com/science/article/abs/pii/S037851732201105X
  125. https://www.geneesmiddeleninformatiebank.nl/pars/h110264.pdf
  126. https://www.ema.europa.eu/en/medicines/psusa/psusa-00000034-202309
  127. https://cdn.who.int/media/docs/default-source/essential-medicines/2021-eml-expert-committee/applications-for-new-indications-for-existing-listed-medicines/i.13_n-acetylcysteine.pdf?sfvrsn=6945b088_4
  128. https://www.fda.gov/media/157784/download
  129. https://community.the-hospitalist.org/content/hunt-n-acetylcysteine-medicine-or-dietary-supplement
  130. https://www.supplysidesj.com/supplement-regulations/fda-warning-letters-on-nac-cause-stir-in-supplement-sector
  131. https://www.thefdalawblog.com/2021/12/npa-files-complaint-seeking-to-prevent-fda-from-applying-the-exclusionary-clause-retroactively/
  132. https://www.thefdalawblog.com/2024/09/the-national-products-association-challenges-fdas-interpretation-of-the-dietary-supplement-exclusionary-clause/
  133. https://downloads.regulations.gov/FDA-2021-P-0938-0001/attachment_2.pdf
  134. https://www.fda.gov/food/hfp-constituent-updates/fda-requests-information-relevant-use-nac-dietary-supplement
  135. https://www.fda.gov/food/hfp-constituent-updates/fda-issues-response-two-citizen-petitions-nac-dietary-supplements
  136. https://natlawreview.com/article/fda-confirms-n-acetyl-l-cysteine-nac-excluded-dietary-supplement-definition-and
  137. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-policy-regarding-n-acetyl-l-cysteine
  138. https://www.federalregister.gov/documents/2022/08/02/2022-16499/policy-regarding-n-acetyl-l-cysteine-guidance-for-industry-availability
  139. https://www.fda.gov/food/hfp-constituent-updates/fda-releases-final-guidance-enforcement-discretion-certain-nac-products
  140. https://www.supplysidesj.com/supplement-regulations/fda-is-exploring-rulemaking-for-nac-supplements
  141. https://www.psychiatrist.com/jcp/n-acetylcysteine-ptsd-alcohol-use-disorder-randomized-controlled-trial/
  142. https://pubmed.ncbi.nlm.nih.gov/32087337/
  143. https://pubmed.ncbi.nlm.nih.gov/31941795/
  144. https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed_citedin&from_uid=40163249
  145. https://pubmed.ncbi.nlm.nih.gov/31805012/
  146. https://pubmed.ncbi.nlm.nih.gov/34114174/
  147. https://pmc.ncbi.nlm.nih.gov/articles/PMC9878233/
  148. https://pubmed.ncbi.nlm.nih.gov/38641841/
  149. https://pubmed.ncbi.nlm.nih.gov/33560443/
  150. https://pubmed.ncbi.nlm.nih.gov/39108325/
  151. https://pubmed.ncbi.nlm.nih.gov/32845997/
  152. https://pubmed.ncbi.nlm.nih.gov/39790357/
  153. https://www.tandfonline.com/doi/full/10.1080/17582024.2025.2563489?src=exp-la
  154. https://cdnsciencepub.com/doi/10.1503/jpn.100057
  155. https://www.sciencedirect.com/science/article/pii/S0149763415001190
  156. https://www.researchgate.net/publication/261187118_Systematic_review_of_N-acetylcysteine_in_the_treatment_of_addictions
  157. https://pmc.ncbi.nlm.nih.gov/articles/PMC10659758/
  158. https://pmc.ncbi.nlm.nih.gov/articles/PMC11617117/
  159. https://www.cpn.or.kr/journal/view.html?uid=1494&vmd=Full
  160. https://pmc.ncbi.nlm.nih.gov/articles/PMC8092890/
Add your contribution
Related Hubs
User Avatar
No comments yet.